BioCentury | Oct 19, 2018
Clinical News

Opdivo misses survival endpoint in Phase III for SCLC

...enrolled 803 patients to receive Opdivo or standard of care (SOC) chemotherapy with topotecan or amrubicin...
BioCentury | Oct 12, 2018
Clinical News

Opdivo misses survival endpoint in Phase III for SCLC

...about 803 patients to receive Opdivo or standard of care (SOC) chemotherapy with topotecan or amrubicin...
BioCentury | Sep 10, 2012
Clinical News

Calsed amrubicin regulatory update

...Dainippon submitted a regulatory application to China's State Food and Drug Administration (SFDA) for amrubicin as...
...third-generation synthetic anthracycline from Dainippon. Nippon Kayaku Co. Ltd. (Tokyo:4272, Tokyo, Japan) markets amrubicin as Calsed...
...Corp. (NASDAQ:CELG), Summit, N.J. Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506), Osaka, Japan Product: Calsed amrubicin...
BioCentury | Aug 23, 2012
Distillery Therapeutics

Indication: Cancer

...non-small cell lung cancer (NSCLC). Dainippon Sumitomo Pharma Co. Ltd. and Celgene Corp. market Calsed amrubicin...
BioCentury | Mar 19, 2012
Strategy

Incentivized success

...tumor 1 (WT1) peptide vaccine in Phase I/II testing for myelodysplastic syndrome (MDS); and Calsed amrubicin...
...is partnered with Roche 's Chugai Pharmaceutical Co. Ltd. unit. Nippon Kayaku Co. Ltd. markets Calsed...
...an agreement with Dainippon. Celgene Corp. , which has North American and European rights to amrubicin...
BioCentury | Jul 4, 2011
Finance

2Q Stock Wrap-Up: Stand and deliver

...influenza to other family members of a patient with confirmed influenza infection Celgene Corp. (NASDAQ:CELG) Amrubicin...
BioCentury | May 23, 2011
Finance

Highlights of weekly biotech stock moves

...Celgene Corp. (NASDAQ:CELG) gained $0.55 to $60.49 last week despite reporting that second-line treatment with amrubicin...
BioCentury | May 23, 2011
Clinical News

Calsed amrubicin: Phase III data

...The open-label, international Phase III ACT-1 trial in 637 patients showed that IV amrubicin as second-line...
...Oncology meeting in Chicago in June. Nippon Kayaku Co. Ltd. (Tokyo:4272, Tokyo, Japan) markets Calsed amrubicin...
...Corp. (NASDAQ:CELG), Summit, N.J. Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506), Osaka, Japan Product: Calsed amrubicin...
BioCentury | May 20, 2011
Clinical News

Amrubicin misses in lung cancer

...Second-line treatment with amrubicin from Celgene Corp. (NASDAQ:CELG) missed the primary endpoint of significantly improving overall...
...to an abstract released ahead of the American Society of Clinical Oncology meeting. Patients receiving amrubicin...
...OS. The open-label, international trial enrolled 637 patients. The meeting starts June 3 in Chicago. Amrubicin...
BioCentury | Oct 4, 2010
Finance

4Q10 milestones

...Istodax romidepsin PTCL Submit sNDA 4Q10 Celgene Corp. (NASDAQ:CELG)/Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) Amrubicin...
Items per page:
1 - 10 of 44